Initiated Buy X

OCUL Ocular Therapeutix

Needham

$15

Initiated Sector Outperform X

OCUL Ocular Therapeutix

Scotiabank

Upgrades Hold Buy X

OCUL Ocular Therapeutix

TD Cowen

$7 $11

Resumed Overweight X

OCUL Ocular Therapeutix

Piper Sandler

$15

Initiated Buy X

OCUL Ocular Therapeutix

BofA Securities

$15

Initiated Outperform X

OCUL Ocular Therapeutix

Robert W. Baird

$18

Resumed Buy X

OCUL Ocular Therapeutix

Berenberg

$15

Downgrades Buy Neutral X

OCUL Ocular Therapeutix

H.C. Wainwright

Downgrades Outperform Mkt Perform X

OCUL Ocular Therapeutix

Cowen

$13 $3

Reiterated Buy X

OCUL Ocular Therapeutix

H.C. Wainwright

$12 $9

Downgrades Strong Buy Outperform X

OCUL Ocular Therapeutix

Raymond James

$11 $5

Reiterated Overweight X

OCUL Ocular Therapeutix

Cantor Fitzgerald

$22 $24

Initiated Strong Buy X

OCUL Ocular Therapeutix

Raymond James

$10

Initiated Overweight X

OCUL Ocular Therapeutix

Piper Jaffray

OCUL  Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.